As per MRFR analysis, the US Psoriasis Treatment Market Size was estimated at 1.62 (USD Billion) in 2023. The US Psoriasis Treatment Market Industry is expected to grow from 1.79 (USD Billion) in 2024 to 2.98 (USD Billion) by 2035. The US Psoriasis Treatment Market CAGR (growth rate) is expected to be around 4.743% during the forecast period (2025 - 2035).
The US Psoriasis Treatment Market is witnessing significant trends driven by increased awareness of psoriasis and its treatments. Patients are becoming more informed about their options, encouraging demand for effective therapies. The growing prevalence of psoriasis in the US, attributed to factors such as obesity, smoking, and stress, propels the market forward. There is a notable shift towards biologic therapies, which provide targeted treatment methods for moderate to severe cases. These advancements in precision medicine are replacing traditional treatments, providing better efficacy and fewer side effects. The rise of telemedicine has also changed how patients access care, allowing for easier consultations with dermatologists, which is particularly beneficial for those in remote areas or with mobility challenges.
Opportunities within this market include the development of personalized medicine, combining genetic research and new treatment modalities tailored to individual patient needs. Additionally, guided patient education and support programs have opened avenues for pharmaceutical companies to engage with patients, improve treatment adherence, and enhance quality of life. Recent trends indicate an increased focus on combination therapies, where multiple treatments are used together to achieve better management of the condition. Moreover, ongoing research and innovations continue to emerge, with new drug candidates entering clinical trials that may enhance treatment effectiveness and safety. This is particularly pertinent in the US, where regulatory pathways are advancing rapidly, reflecting a supportive environment for the introduction of innovative therapies. Overall, the US Psoriasis Treatment Market is on an upward trajectory, driven by both patient demand and the continuous evolution of treatment options.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The increasing prevalence of psoriasis in the United States is a significant driver for the US Psoriasis Treatment Market Industry. According to data from the National Psoriasis Foundation, an estimated 7.5 million Americans are living with psoriasis, which is roughly 2-3% of the U.S. population. This increasing prevalence leads to greater demand for effective treatments, driving market growth. The population's awareness regarding skin diseases has also surged, resulting in a higher rate of diagnoses and subsequent treatment initiation.
This trend is further supported by the development of innovative therapies. For example, companies such as Amgen and Johnson & Johnson have launched biologics that are transforming treatment paradigms, making psoriasis management more effective and tailored, thus expanding the patient base seeking treatment.
Innovative therapies and advancements in treatment options can significantly propel the US Psoriasis Treatment Market Industry. The introduction of biologics and targeted therapies has changed the approach to managing psoriasis, leading to higher efficiency and better patient outcomes. The American Academy of Dermatology notes that biologic treatments have undergone rapid development over the past few years, with multiple new products being approved by the U.S. Food and Drug Administration. This not only increases competition among pharmaceutical companies but also provides healthcare providers with an expanded toolkit to manage psoriasis.
As a result, the availability of diverse treatment options is expected to grow, appealing to a wider range of patients and contributing to market growth.
Rising patient awareness regarding psoriasis and its treatments is increasingly driving the US Psoriasis Treatment Market Industry. Various awareness campaigns conducted by organizations such as the National Psoriasis Foundation and American Academy of Dermatology focus on educating the public about skin health and the importance of seeking treatment. As more individuals recognize the symptoms and impact of psoriasis on their quality of life, they are more likely to seek medical attention.
A survey indicates that awareness regarding psoriasis has improved by nearly 35% among the general population over the past five years, which is pivotal in aiding early diagnosis and facilitating appropriate treatment pathways.
The growth of investment in healthcare infrastructure is also a vital driver for the US Psoriasis Treatment Market Industry. According to the Centers for Medicare and Medicaid Services, the U.S. healthcare spending is projected to grow at an average rate of 5.4% per year, reaching a substantial part of the GDP. This surge provides healthcare providers with improved resources, technologies, and facilities to manage and treat psoriasis effectively. Improved access to dermatology specialists and treatment centers translates into more patients receiving timely care.
Furthermore, robust investment in Research and Development by companies like Pfizer and AbbVie enhances the overall medication pipeline, driving better treatment options and improved patient outcomes.
The Treatment Type segment within the US Psoriasis Treatment Market encompasses a diverse range of therapeutic options aimed at addressing this chronic skin condition that affects millions in the United States. Topical Treatments, which are often the first line of defense, play a crucial role in managing symptoms by applying medications directly to the skin, thereby providing targeted relief for localized areas. Systemic Treatments are employed for more severe cases, offering comprehensive management through medications that work throughout the body, appealing particularly to individuals with widespread psoriasis or those unresponsive to topical therapies. Phototherapy utilizes specific wavelengths of light to treat psoriasis effectively; this option not only serves as a critical alternative for many patients but is also endorsed for its potential to minimize systemic exposure to pharmaceuticals.
The increasing popularity of Biologics represents a significant shift in the market as they specifically target immune responses involved in psoriasis development, showcasing advanced mechanisms of action that help improve the quality of life for those affected. Overall, each treatment type contributes uniquely to the dynamic landscape of the US Psoriasis Treatment Market, responding to the varying needs of patients while highlighting ongoing advancements in dermatological therapies. The increasing awareness regarding treatment options, accompanied by the ongoing Research and Development in this sector, drives market growth and encourages patients and healthcare providers alike to explore these effective solutions. As the treatment modalities evolve, understanding the nuances of each type continues to be pivotal for stakeholders in optimizing approaches for managing psoriasis, ultimately aiming to enhance patient outcomes and quality of life.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The US Psoriasis Treatment Market has seen significant developments in its Administration Route segment, reflecting various approaches to patient care. This segment highlights the diverse methods available for delivering treatments, including Oral, Topical, Injectable, and Intravenous routes. Topical treatments are prominently used due to their localized effect, providing relief with minimal systemic exposure, and are often preferred for mild to moderate cases. In contrast, Injectable therapies have gained traction, especially with the advent of biologics, which target specific pathways in the immune response associated with psoriasis, offering more effective outcomes for severe cases.
Intravenous administration, although less common, plays a vital role in providing rapid treatment for patients needing immediate relief. Oral therapies remain popular as they offer convenience and ease of use, appealing to a broad patient base. These varied administration routes not only cater to the diverse needs of patients but also adapt to evolving treatment paradigms in the US, thereby enhancing overall treatment adherence and effectiveness. The continuous introduction of novel therapies through these routes reflects ongoing Research and Development efforts aimed at improving patient outcomes in the management of psoriasis.
The US Psoriasis Treatment Market is characterized by various indications that highlight the diverse needs of patients suffering from this chronic skin condition. Among these indications, Plaque Psoriasis is particularly significant, as it affects the majority of psoriasis patients with well-defined, raised lesions. Guttate Psoriasis, often triggered by infections, presents a different challenge and is more common in children and young adults, emphasizing the need for age-appropriate treatments. Inverse Psoriasis, which occurs in skin folds, can be challenging to manage due to its sensitivity and the discomfort it causes, while Pustular Psoriasis, although less common, requires effective intervention due to the potential severity of symptoms.
The distinctions among these indications lead to differing treatment approaches, thereby influencing the US Psoriasis Treatment Market segmentation. This variability within the indication segment is crucial as it informs healthcare providers and pharmaceutical companies about the specific requirements for effective management of psoriasis, thereby driving innovation and developments in treatment therapies tailored for each type.
The End User segment of the US Psoriasis Treatment Market includes hospitals, dermatology clinics, and homecare settings, each playing a vital role in the management and treatment of psoriasis. Hospitals signify a substantial portion of the market, equipped with advanced facilities and specialists that offer comprehensive care for severe cases. Dermatology clinics focus particularly on skin-related conditions, providing targeted therapies and support, making them a preferred choice for patients seeking specialized attention. Homecare settings are becoming increasingly significant, enabling patients to manage their treatment in the comfort of their homes, which is important for those seeking convenience and personalized care.
The rise in the prevalence of psoriasis in the United States, along with increasing awareness about treatment options and the growing demand for tailored therapies, fuel the growth of these segments. Moreover, the integration of telehealth services is enhancing accessibility in dermatology clinics and homecare settings, making it easier for patients to receive ongoing medical advice. This diverse segmentation highlights the various pathways of care available to individuals suffering from psoriasis, illustrating the evolving landscape of treatment options in the US Psoriasis Treatment Market.
The US Psoriasis Treatment Market is characterized by intense competition, driven by a rising prevalence of psoriasis among the population, awareness regarding treatment options, and advancements in therapeutic technologies. This market includes a diverse range of treatment modalities, including biologics, systemic therapies, and topical treatments, which cater to different severity levels and patient preferences. As research and development continue to innovate in this space, various pharmaceutical companies are striving to secure their positions through strategic collaborations, product launches, and expanding their portfolios. The landscape is also influenced by regulatory frameworks, pricing strategies, and the burgeoning demand for tailored therapies to enhance patient outcomes. All these factors play a vital role in shaping the competitive dynamics of the market.
Celgene holds a notable position within the US Psoriasis Treatment Market, particularly recognized for its commitment to developing innovative therapies that address the unmet needs of psoriasis patients. The company's strength lies in its robust pipeline, which includes several biologics that demonstrate significant efficacy in treating moderate to severe psoriasis. This focus on research and development has positioned Celgene as a formidable player in the market, allowing it to leverage its existing product portfolio and expand its therapeutic options. Furthermore, Celgene's strong sales and marketing strategies enhance its visibility among healthcare professionals, while its commitment to patient support programs underscores its dedication to improving treatment adherence and patient satisfaction in the US region.
Novartis is another key competitor in the US Psoriasis Treatment Market, with a strong emphasis on developing integrated treatment solutions that cater to diverse patient needs. The company is known for its leading products that have become go-to options for the management of psoriasis. Novartis has strategically expanded its market presence through a series of mergers and acquisitions, which have significantly bolstered its portfolio of psoriasis therapies. Their investments in innovative therapies, including biologics and targeted therapies, have established Novartis as a market leader. Additionally, Novartis focuses on patient-centric approaches, ensuring that its offerings not only meet clinical efficacy but also improve overall quality of life for individuals suffering from psoriasis. The company's robust distribution network further amplifies its reach within the US market, contributing to its competitive stance in the rapidly evolving landscape of psoriasis treatments.
In recent developments within the US Psoriasis Treatment Market, significant advancements have been made by major players such as Novartis and AbbVie, launching upgraded formulations that have shown improved efficacy in clinical trials. For example, AbbVie's drug Humira continues to dominate the market while new entrants are closely following. Moreover, in September 2023, Regeneron Pharmaceuticals announced a strategic partnership with Sanofi to enhance the delivery of their eczema and psoriasis therapies, showcasing collaboration among leading firms. Current affairs reflect a growing consumer demand for personalized medicine, prompting companies like Eli Lilly and Amgen to invest heavily in Research and Development for biologic treatments.
In merger and acquisition news, Bristol Myers Squibb completed its acquisition of Myokardia in October 2023, aimed at expanding its cardiovascular portfolio, which may indirectly impact its psoriasis product strategy. Market valuation has steadily grown, with the US Psoriasis Treatment Market estimated to reach $12 billion by 2025, primarily driven by innovative drugs and increasing prevalence rates as reported by the Centers for Disease Control and Prevention (CDC). Such growth highlights an evolving landscape with promising opportunities for both established companies and newcomers entering the psoriasis treatment sector.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 1.62(USD Billion) |
| MARKET SIZE 2024 | 1.79(USD Billion) |
| MARKET SIZE 2035 | 2.98(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.743% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Celgene, Novartis, Dermira, Eli Lilly, GlaxoSmithKline, BristolMyers Squibb, Mylan, Regeneron Pharmaceuticals, Incyte, Pfizer, Amgen, AbbVie, Sanofi, Johnson and Johnson, UCB |
| SEGMENTS COVERED | Treatment Type, Administration Route, Indication, End User |
| KEY MARKET OPPORTUNITIES | Biologic therapies adoption growth, Personalized treatment advancements, Increased awareness and diagnosis, Expansion of telehealth services, Rising demand for natural remedies |
| KEY MARKET DYNAMICS | Increasing prevalence of psoriasis, Growing demand for biologics, Advancements in personalized medicine, Rising awareness and education, Regulatory support for new therapies |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The US Psoriasis Treatment Market is expected to be valued at 1.79 billion USD in 2024.
By 2035, the market is projected to grow to 2.98 billion USD.
The market is expected to experience a CAGR of 4.743% from 2025 to 2035.
Topical treatments are expected to dominate the market, valued at 0.75 billion USD in 2024.
Systemic treatments are projected to reach a market value of 0.9 billion USD by 2035.
Major players include Celgene, Novartis, Dermira, Eli Lilly, and GlaxoSmithKline.
Biologics are expected to reach a market size of 0.48 billion USD by 2035.
The phototherapy segment is projected to be valued at 0.4 billion USD by 2035.
Growth drivers include increasing prevalence of psoriasis and advancements in treatment options.
Challenges include high treatment costs and limited patient awareness about available therapies.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager
He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
